抑郁症患者血清hs-CRP水平变化及其对抗抑郁药疗效的预测作用

doi:10.6040/j.issn.1671-7554.0.2017.261

摘要/Abstract

摘要： 目的探讨抑郁症患者血清超敏C反应蛋白(hs-CRP)水平在治疗前后的变化,以及基线hs-CRP水平对抗抑郁药疗效的预测作用。方法 61例抑郁症患者(研究组)随机分为舍曲林治疗亚组(30例)和度洛西汀治疗亚组(31例),疗程8周,于基线及8周末测hs-CRP水平,并评定HAMD量表。32例健康受试者(对照组)在入组及8周后测hs-CRP水平。结果研究组基线hs-CRP水平高于对照组,抗抑郁治疗后显著下降,但仍高于同期对照组(P<0.05),研究组治疗前、后hs-CRP水平与HAMD评分均呈正相关(P<0.05)。度洛西汀亚组基线hs-CRP≥3 mg/L者的有效率及HAMD-17减分率显著高于<3 mg/L者;在基线hs-CRP≥3 mg/L的患者中,度洛西汀的有效率显著高于舍曲林。二元Logistic回归分析显示,基线hs-CRP水平、亚组组别×基线hs-CRP水平进入疗效的回归方程,析因设计的方差分析结果显示药物和基线hs-CRP水平的交互作用对疗效有一定的影响(P<0.05)。结论炎症反应参与了抑郁症的病理机制,血清hs-CRP水平可能在一定程度上反映抑郁严重程度;度洛西汀对基线hs-CRP水平较高的抑郁症患者可能有更好疗效,但尚需更大样本量的研究进行验证。

关键词: 抑郁症, 超敏C反应蛋白, 炎症, 度洛西汀, 舍曲林

Abstract: Objective To explore the changes of high sensitivity C reactive protein(hs-CRP)level before and after antidepressant treatment, as well as the predictive role of hs-CRP level at baseline for the efficiency of antidepressants. Methods A total of 61 patients with depression(study group)were randomized into the sertraline subgroup(n=30)and duloxetine subgroup(n=31). At baseline and the end of 8-week treatment, the serum level of hs-CRP was measured, and Hamilton Depression Scale-17 items(HAMD-17)were evaluated. Additionally, serum hs-CRP level was measured in 32 well-matched healthy controls(control group)and re-measured 8 weeks later. Results At baseline, the serum level of hs-CRP was higher in the study group than in control group, and it decreased significantly after 8-week treatment but was still significantly higher than that in the control group at the endpoint(P<0.05). Serum hs-CRP level in the study group was positively correlated with HAMD-17 score at baseline and endpoint(P<0.05). In the duloxetine subgroup, the effective rate and reduction rate of HAMD-17 in patients with higher level of baseline hs-CRP(≥3 mg/L)were significantly higher than those in patients with lower baseline hs-CRP(<3 mg/L)(P<0.05). Moreover, in patients with higher baseline hs-CRP level, the effective rate of duloxetine was significantly higher than that of sertraline(P<0.05). Binary Logistic regression analysis indicated that baseline hs-CRP level and subgroup × baseline hs-CRP level 山东大学学报 (医学版)56卷6期 -王丹,等.抑郁症患者血清hs-CRP水平变化及其对抗抑郁药疗效的预测作用 \=-entered the regression equation of efficacy. Factorial design ANOVA illustrated that interaction between antidepressant and baseline hs-CRP level had certain effects on the efficacy of treatment(P<0.05). Conclusion Elevated inflammatory response is involved in the pathophysiology of depression. Serum hs-CRP level may partly reflect the severity of depression. Depressive patients with high baseline hs-CRP level are more likely to respond to duloxetine. Validation in a larger sample is warranted.

Key words: Depression, High sensitivity C reactive protein, Inflammation, Duloxetine, Sertraline

中图分类号:

R749.4

王丹,杨晓华,郑云哨,阚伟京,寻广磊. 抑郁症患者血清hs-CRP水平变化及其对抗抑郁药疗效的预测作用[J]. 山东大学学报 (医学版), 2018, 56(6): 51-57.

WANG Dan, YANG Xiaohua, ZHENG Yunshao, KAN Weijing, XUN Guanglei. Serum level of hs-CRP in patients with depression and its predictive role for the efficiency of antidepressants[J]. Journal of Shandong University (Health Sciences), 2018, 56(6): 51-57.

参考文献

[1] Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression[J]. Biol Psychiatry, 2010, 67(5): 446-457.
[2] Liu Y, Ho RC, Mak A. Interleukin(IL)-6, tumour necrosis factor alpha(TNF-α)and soluble interleukin-2 receptors(sIL-2R)are elevated in patients with major depressive disorder: a meta-analysis and meta-regression[J]. J Affect Disord, 2012, 139(3): 230-239.
[3] Papakostas GI, Shelton RC, Kinrys G, et al. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study[J]. Mol Psychiatry, 2013, 18(3): 332-339.
[4] 张明园, 何燕玲. 精神科评定量表手册[M]. 2版. 长沙: 湖南科学技术出版社, 2015: 142-148.
[5] Maes M. Evidence for an immune response in major depression: a review and hypothesis[J]. Prog Neuropsychopharmacol Biol Psychiatry, 1995, 19(1): 11-38.
[6] Vreeburg SA, Hoogendijk WJ, van Pelt J, et al. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study[J]. Arch Gen Psychiatry, 2009, 66(6): 617-626.
[7] Licht CM, de Geus EJ, Zitman FG,et al. Association between major depressive disorder and heart rate variability in the Netherlands Study of Depression and Anxiety(NESDA)[J]. Arch Gen Psychiatry, 2008, 65(12): 1358-1367.
[8] Marsland AL, Gianaros PJ, Abramowitch SM, et al. Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults[J]. Biol Psychiatry, 2008, 64(6): 484-490.
[9] Blank T, Detje CN, Spieß A, et al. Brain endothelial- and epithelial-specific interferon receptor chain 1 drives virus-induced sickness behavior and cognitive impairment[J]. Immunity, 2016, 44(4): 901-912.
[10] Khairova RA, Machado-Vieira R, Du J, et al. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder[J]. Int J Neuropsychopharmacology, 2009, 12(4): 561.
[11] Dantzer R, O’Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain[J]. Nat Rev Neurosci, 2008, 9(1): 46-56.
[12] Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression[J]. Mol Psychiatry, 2011, 16(7): 751-762.
[13] Valkanova V, Ebmeier KP, Allan CL. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies[J]. J Affect Disord, 2013, 150(3): 736-744.
[14] Wium-Andersen MK, Ørsted DD, Nielsen SF, et al. Elevated C-reactive protein levels, psychological distress, and depression in 73131 individuals[J]. JAMA Psychiatry, 2013, 70(2): 176-184.
[15] Lopresti AL, Maker GL, Hood SD, et al. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2014, 48(1433): 102-111.
[16] Vogelzangs N, Duivis HE, Beekman AT, et al. Association of depressive disorders, depression characteristics and antidepressant medication with inflammation[J]. Transl Psychiatry, 2012, 2(2): e79. doi: 10.1038/tp.2012.8.
[17] Copeland WE, Shanahan L, Worthman C, et al. Cumulative depression episodes predict later C-reactive protein levels: a prospective analysis[J]. Biol Psychiatry, 2012, 71(1): 15-21.
[18] Zalli A, Jovanova O, Hoogendijk WJ, et al. Low-grade inflammation predicts persistence of depressive symptoms[J]. Psychopharmacology(Berl), 2016, 233(9): 1669-1678.
[19] Almeida OP, Norman PE, Allcock R, et al. Polymorphisms of the CRP gene inhibit inflammatory response and increase susceptibility to depression: the Health in Men Study[J]. Int J Epidemiol, 2009, 38(4): 1049-1059.
[20] Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review[J]. Am J Psychiatry, 2000, 157(6): 867-876.
[21] Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trail of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers[J]. JAMA Psychiatry, 2013, 70(1): 31-41.
[22] Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression[J]. Biol Psychiatry, 2009, 65(9): 732-741.
[23] Chavda N, Kantharia ND, Jaykaran. Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression[J]. J Pharmacol Pharmacother, 2011, 2(1): 11-16.
[24] Felger JC, Li Z, Haroon E, et al. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression[J]. Mol Psychiatry, 2016, 21(10): 1358-1365.
[25] Mowla A, Dastgheib SA, Razeghian Jahromi L. Comparing the effects of sertraline with duloxetine for depression severity and symptoms: a double-blind, randomized controlled trial[J]. Clin Drug Investig, 2016, 36(7): 539-543.
[26] Uher R, Tansey KE, Dew T, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline[J]. Am J Psychiatry, 2014, 171(12): 1278- 1286.

相关文章 15

[1]	徐宁宇王磊郝恩魁苏国海. STEMI患者急诊PCI前口服阿托伐他汀对炎症介质及左心室功能的影响[J]. 山东大学学报(医学版), 2209, 47(6): 69-72.
[2]	郝跃伟刘雪平赵婷婷郑敏王一兵. 环氧化酶2基因多态性与动脉粥样硬化缺血性脑卒中的相关性[J]. 山东大学学报(医学版), 2209, 47(6): 95-98.
[3]	樊呈敏,宋静雨,于书彦,毛雪琴. 舒肝解郁胶囊治疗青少年抑郁障碍的研究进展[J]. 山东大学学报 (医学版), 2026, 64(3): 17-23.
[4]	陈婵,李巨章,何稳,吴巧珍. 基于两样本孟德尔随机化研究抑郁症和抗抑郁药物靶基因与睡眠呼吸暂停的关联[J]. 山东大学学报 (医学版), 2026, 64(1): 28-36.
[5]	赵灿斌,邵将,管东辉,秦英,丁强,郭良,王伟伟,陈威,闫小龙,曾平. 木犀草素在炎症微环境下调控Wnt/β-catenin信号通路促进骨髓间充质干细胞成软骨分化的机制[J]. 山东大学学报 (医学版), 2025, 63(7): 11-22.
[6]	贾若曦,吕丽,刘涵云,吴寅平,李凤彩,赵泽华,王凯,范玉琛. 血细胞计数相关标志物对慢加急性乙型肝炎肝衰竭患者28天预后的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(6): 89-99.
[7]	张舒淇,江延姣,印丹. 生殖道微生物与子宫内膜异位症发展之间的联系[J]. 山东大学学报 (医学版), 2025, 63(5): 120-126.
[8]	杜艾家,张曼,陈鹤,王丽新,尚应殊. 微小RNA-1270靶向调控血管生成素样蛋白7抑制巨噬细胞炎症和脂质蓄积[J]. 山东大学学报 (医学版), 2025, 63(2): 1-9.
[9]	徐萍,张信美. 子宫内膜异位症疼痛的机制[J]. 山东大学学报 (医学版), 2025, 63(10): 1-7.
[10]	梁炎春,严莹,麦华希,姚书忠. 地诺孕素在子宫内膜异位症相关性疼痛中的治疗作用:从基础到临床[J]. 山东大学学报 (医学版), 2025, 63(10): 27-33.
[11]	孙婧,杨瑞敏,王聪,张月,罗兵. 基于术前超声、炎症指标及超声影像组学联合模型预测乳腺癌腋窝淋巴结转移[J]. 山东大学学报 (医学版), 2025, 63(1): 73-80.
[12]	刘绍庭,张薇薇,冉茜,王建. 食品乳化剂与肠道健康[J]. 山东大学学报 (医学版), 2024, 62(8): 18-26.
[13]	孙丽娜,白红艳,牛宗格,张福帅,曲仪庆. 基于SII构建及评价预测ARDS住院死亡率的在线临床风险模型[J]. 山东大学学报 (医学版), 2024, 62(7): 10-20.
[14]	田丽君,桑玉洁,孙瑜婧,韩冰,秦成勇,祁建妮. 全身免疫炎症指数对原发性肝癌患者免疫检查点抑制剂治疗相关不良反应的预测价值[J]. 山东大学学报 (医学版), 2024, 62(6): 48-53.
[15]	沈海涛,乔亚琴,董萍,路燕. Toll样受体4调控的程序性坏死和铁死亡对对乙酰氨基酚肝损伤的影响[J]. 山东大学学报 (医学版), 2024, 62(4): 1-8.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed